Daiichi Sankyo to boost ADC manufacturing; Eli Lilly looks to outer space; new FDA initiative for manufacturing tech

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more. This week, we look in­to Eli Lil­ly join­ing Red­wire’s ini­tia­tive to man­u­fac­ture phar­ma­ceu­ti­cals in space, as well as Ex­ela Phar­ma’s re­call of three in­jecta­bles.

Dai­ichi Sankyo boosts ADC ca­pac­i­ty 

Dai­ichi Sankyo is ab­sorb­ing two of its whol­ly-owned man­u­fac­tur­ing com­pa­nies, Dai­ichi Sankyo Prophar­ma and Dai­ichi Sankyo Chem­i­cal Phar­ma, ef­fec­tive April 2025. An­nounced on Tues­day, the move ex­pands Dai­ichi’s ca­pac­i­ty to sup­ply and man­u­fac­ture an­ti­body-drug con­ju­gates, as well as de­vel­op new modal­i­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.